The risk of cardiovascular disease in Ankylosing Spondylitis: A Single Center Cross-Sectional Study Evaluating The Association Between Inflammation In Ankylosing Spondylitis And Vascular Inflammation

Published: 21-09-2012
Last updated: 26-04-2024

To establish compare vessel wall dimensions and inflammation in AS with healthy matched control subjects with MRI and PET-FDG

Ethical review	Approved WMO
Status	Recruitment stopped
Health condition type	Coronary artery disorders
Study type	Observational invasive

Summary

ID

NL-OMON37301

Source
ToetsingOnline

Brief title
AS-Risk

Condition

- Coronary artery disorders
- Autoimmune disorders
- Arteriosclerosis, stenosis, vascular insufficiency and necrosis

Synonym
Bechterew

Research involving
Human

Sponsors and support

Primary sponsor: Academisch Medisch Centrum
Source(s) of monetary or material Support: Afdeling Vasculaire Geneeskunde

Intervention

Keyword: Ankylosing Spondylitis, Cardiovascular risk, Inflammation

Outcome measures

Primary outcome

Difference in TBR between AS patients and controls

Secondary outcome

-Carotid artery dimensions

Study description

Background summary

Ankylosing Spondylitis (AS) is a systemic inflammatory disease characterized by axial joint involvement, sacroiliitis and various extra-articular manifestations. It has been suggested that atherogenesis may be enhanced in AS as an increased cardiovascular mortality has been reported. The inflammatory process in the vessel walls, leading to atherosclerosis, may be amplified by the presence of systemic inflammation due to AS. FDG-PET is a novel imaging technique to quantify vessel wall inflammation.

Study objective

To establish compare vessel wall dimensions and inflammation in AS with healthy matched control subjects with MRI and PET-FDG

Study design

The study objective will be addressed by a cross-sectional study.

Study burden and risks

Patients will visit the department for 6 hours. The withdrawal of blood and infusion of FDG contrast may cause light reactions or a blue spot. No extra discomfort is expected. A moderate radiationload is expected as a consequence of performing the PET-CT scan.

Contacts

Public
Academisch Medisch Centrum

Meibergdreef 9
Amsterdam 1105AZ
NL
Scientific
Academisch Medisch Centrum

Meibergdreef 9
Amsterdam 1105AZ
NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age
Adults (18-64 years)
Elderly (65 years and older)

Inclusion criteria

Subjects with AS
-Age: above18 years
-Diagnosis of AS + disease duration since start of first symptoms for a period of more than 3

years.

Exclusion criteria

Subjects may not enter this study if they meet the following criteria
-BMI > 30.
-history of diabetes mellitus/insulin use
-hypertension/use of blood pressure lowering medication
-use of statins
-history of cardiovascular events
-proven or suspected bacterial infections.
-use of anti-inflammatory medication from group "biologicals"

Study design

Design

Study type: Observational invasive

Masking:	Open (masking not used)
Control:	Uncontrolled
Primary purpose:	Basic science

Recruitment

NL

Recruitment status:	Recruitment stopped
Start date (anticipated):	16-11-2012
Enrollment:	25
Type:	Actual

Ethics review

Approved WMO

Date:	21-09-2012
Application type:	First submission
Review commission:	METC Amsterdam UMC

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
CCMO	NL40662.018.12